Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer Academic Article uri icon


  • We present the case of a patient with multiple EGFR mutations that highlights tumor heterogeneity leading to a mixed response to osimertinib and emphasizes the complexity of EGFR-driven lung cancer. Subclonal tumor evolution was proved by tissue biopsy, monitored by serial analyses of cell-free circulating tumor DNA (cfDNA) at disease progression, and addressed using EGFR tyrosine kinase inhibitor (TKI) combination therapy.

publication date

  • July 1, 2017